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Success in Recruitment to
Randomized Clinic Trials
Keep it Simple and Close to Home . . .
or Is There More to It?*
Robert L. Frye, MD
Rochester, Minnesota
Randomized clinical trials (RCTs) are accepted as the best
way to evaluate the effectiveness of treatments, but have
been consistently plagued by difficulties in recruiting enough
participants. Most RCTs take longer than expected to
recruit the planned sample size, or miss their enrollment
targets completely. Clearly, we need to understand how to
recruit participants in these important studies.
See page 762
In this issue of the Journal, Martin et al. (1) report an
nteresting analysis of factors that influenced whether pa-
ients approached for participation in randomized trials
greed to be enrolled and randomized. The investigators
nalyzed data from screening logs of 15 cardiovascular
andomized trials conducted at Duke University Medical
enter, and identified the trial-specific and patient-specific
actors that significantly affected study participation. Based
n a careful multivariable analysis, the authors conclude
everal trial-specific factors had a significant, negative effect
n participation, namely, longer trial duration and more
rotocol-driven tests. They also found that the patient-
pecific factors most associated with nonparticipation were
lder age and female. Interestingly, a patient’s level of
ducation, income, and race did not seem to have an effect
pon willingness to participate in an RCT.
Professor Peter Sleight (2) once noted that “Simple trials
nswer the questions rapidly and effectively. The mechanics
f the trial do not hinder patient entry by participating
octors and nurses.” His comments are consistent with the
ndings of Martin et al. (1), and remind investigators
lanning RCTs to “keep it simple.” That is not easy to do,
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the contents of this paper to disclose.as the natural tendency of those engaged in clinical trials is
to explore additional questions by obtaining more data,
which makes the trial more difficult to perform, and may tax
trial participants to the breaking point. My own experience
in the BARI 2D (Bypass Angioplasty Revascularization
Investigation 2 Diabetes) trial, which included close follow-
up, with visits every 3 months to the research site, was that
the protocol was too demanding for many working patients,
as well as for older patients with limited mobility. Partici-
pants frequently commented on the challenge of arranging
transportation to visits or the need to miss work. The
suggestion by Martin et al. (1) to consider innovative
follow-up strategies, such as collecting follow-up data on
the Internet, might make trial participation more attractive
to patients. We should not forget that the patient’s willing-
ness to be a research subject is enhanced when investigators
make it as easy as possible to participate, and omit needless
tests, visits, and questions.
Although it was not an independent predictor, patients
with prior contact with the study center seemed more likely
to agree to participate in RCTs, perhaps reflecting the
importance of familiarity with the study center, and the
support of their personal physician for the recruitment
effort. Evidence abounds of successful recruiting for trials by
individual physicians who practice outside an academic
health center. That suggests that recruitment might be more
successful if the investigators “keep it close to home.”
Improved recruitment of women and the elderly in RCTs
has been identified as a priority, because they may have
distinct clinical characteristics, modes of presentation, and
outcomes. The Duke experience confirms the challenge in
recruiting more women and elderly patients into RCTs. We
need to do better, and we need to identify barriers to their
participation. The lack of an effect of race on patient
willingness to participate in RCTs is a welcome surprise, as
many African Americans lack trust in clinical trials after the
sorry legacy of Tuskegee and other experiments. The
strategies used at Duke to enhance minority recruitment
would be of interest to all.
While recruitment failures and delays in clinical trials
have led to workshops at the Institute of Medicine and
National Heart, Lung, and Blood Institute (3,4) to address
shortfalls, there are also examples of exceptional success in
recruitment to clinical trials. The TIMI (Thrombolysis In
Myocardial Infarction) study group and Duke Clinical
Research Institute regularly recruit large numbers of pa-
tients in a timely manner. We need to understand the basis
for their success. Yet even with their overall success,
recruitment in North America has been declining, and many
trials now depend on foreign sites to enroll sufficient
numbers of patients. For example, only 1,814 of the 18,000
patients recruited in the PLATO (Platelet Inhibition and
Patient Outcomes) trial were from North America.
Why is it necessary to recruit so many patients in other
countries? In my judgment, a key issue in the United States
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February 19, 2013:770–1 Recruitment to Randomized Clinical Trialsis the doctor-patient relationship. The patient comes to the
doctor because of a complaint, not to participate in a trial.
The process of random assignment to a treatment or
strategy may lead to confusion and uncertainty in the mind
of the patient. Do we understand the patient’s true percep-
tions of decisions made by random assignment? While
many argue it is in the patient’s best interest to participate in
a randomized trial, some remain suspicious, exemplified by
a recent book entitled “What the Doctor Didn’t Say: The
Hidden Truth About Medical Research” (5). Patients may
be unwilling to accept randomization if they might not
receive the treatment they regard as the best, or drop out if
they do not receive the treatment they prefer, particularly
when it is available outside the trial. Although most trials
allow for “crossover” to the alternate therapy if deemed
clinically necessary, stories in the press (6) about an episode
in which a patient in a cancer trial was not allowed to cross
over may lead some patients to refuse to participate.
Drazen (7), in an excellent editorial on transparency in
clinical trials, states, “We can make progress in medicine
only if people are willing to put themselves at risk to test
new diagnostic and therapeutic approaches.” In my opinion,
this is the fundamental challenge in recruitment; our ap-
proach must always be guided by the ethical concerns of
Katz (8) regarding the “intertwining of medical science and
medical practice.” From the point of view of the physician
involved in a clinical trial, with equipoise, one should be able
to look the patient in the eye and confess uncertainty about
the best option for treatment or diagnostic strategy; andrecommend trial participation. But what does the patient
actually think? Will understanding the patient’s concept of
the research enhance recruitment? One hopes that Martin et
al. (1) will pursue these challenging questions in future
studies.
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